Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab ASCHIX:GMABC +2.58%98 Debt-to-Equity is 0.89 as of Jun. 2026, which is 4350% above its 10-year median of 0.02. GuruFocus rates CHIX:GMABC with a GF Score™ of 98/100 and a GF Value™ of kr2,277.46 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 967 Biotechnology companies, Genmab AS ranks worse than 86.56% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Genmab AS's Debt-to-Equity or its related term are showing as below:
CHIX:GMABc'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.94
Current: 0.89
During the past 13 years, the highest Debt-to-Equity Ratio of Genmab AS was 0.94. The lowest was 0.01. And the median was 0.02.
CHIX:GMABc's Debt-to-Equity is ranked worse than 86.56% of 967
companies
in the Biotechnology industry
Industry Median: 0.16
vs CHIX:GMABc: 0.89
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Genmab AS Debt-to-Equity Related Terms
Genmab AS Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Genmab AS's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:GMABC vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Genmab AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Genmab AS's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (CHIX:GMABC) has a Debt-to-Equity of 0.89 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Genmab AS and its competitors. This is 4350% above median its historical median of 0.02. Over the past decade, Genmab AS's Debt-to-Equity has ranged from 0.01 to 0.94. According to the industry distribution chart, Genmab AS ranks #837 out of 967 companies in the Biotechnology industry, placing it in the top 86.6%.
Is Genmab AS's Debt-to-Equity too high?
Genmab AS's current Debt-to-Equity of 0.89 is 4350% above median its 10-year median of 0.02. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.94. The Biotechnology industry median Debt-to-Equity is 0.16. Genmab AS's value of 0.89 is 456.3% above this industry median. Based on the distribution chart, Genmab AS ranks #837 out of 967 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genmab AS has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #837 out of 967 companies for Debt-to-Equity. This places Genmab AS in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Genmab AS's value of 0.89 is 456.3% above this benchmark. Historically, Genmab AS's own Debt-to-Equity has ranged from 0.01 to 0.94 over the past decade. While the company's 10-year median is 0.02 vs. the industry median of 0.16, Genmab AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current Debt-to-Equity of 0.89 is 456.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Genmab AS and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Debt-to-Equity is 0.89, which is 4350% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2,277.46, compared to a current price of kr2,025.00 — trading 11.1% below its estimated fair value. The current Debt-to-Equity is 0.89, which is 4350% above median its 10-year median of 0.02 and 456.3% above the Biotechnology industry median of 0.16. Genmab AS's overall GF Score™ is 98/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Debt-to-Equity is 0.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of kr2,025.00 is trading 11.1% below its estimated GF Value™ of kr2,277.46.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for CHIX:GMABC:
Debt-to-Equity: 0.89 (4350% above median its 10-year median of 0.02)
GF Value™: kr2,277.46 vs. price of kr2,025.00 (11.1% below fair value)
Industry Position: 456.3% above the Biotechnology median (#837 of 967)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
98GF Score
Get the complete analysis for CHIX:GMABC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 
